Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. is positioned positively due to strong momentum and optimistic sentiment from Key Opinion Leaders (KOLs) regarding its pipeline candidate PROSERA for pulmonary arterial hypertension (PAH), which is expected to achieve significant treatment effects as reflected in the anticipated 25 to 30-meter improvement in six-minute walk distance (6MWD). Additionally, the Phase 2 TORREY trial data demonstrated consistent benefits across multiple efficacy endpoints, including reductions in pulmonary vascular resistance and pro-BNP levels, along with a robust safety profile and promising durability observed in the open-label extension (OLE) study. The heightened interest from investors following the recent Cantor conference underscores the growing confidence in Gossamer Bio's therapeutic innovations and the potential for market success.

Bears say

Gossamer Bio Inc. faces a negative outlook due to the market's continued mispricing of seralutinib's odds, indicating potential overvaluation in light of its clinical risks. This suggests that investor sentiment may not accurately reflect the challenges and uncertainties surrounding the product's development and commercial prospects. Furthermore, the recent stock run-up may not be justified, potentially leaving investors exposed to future volatility as the company's pipeline products progress through trials.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.